Stocks:
5,169
ETFs:
2,288
Exchanges:
11
Market Cap:
$65.09T
24h Vol:
$8.59B
Dominance:
MSFT:4.90%
Stocklytics Platform
Asset logo for symbol HALO
Halozyme Therapeutics
HALO
81
$49.50arrow_drop_down0.24%-$0.12
High Quality
High Growth

Performance History

Chart placeholder
Key Stats
Open$49.10
Prev. Close$49.62
EPS2.41
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$5.44B
PE Ratio20.54
LOWHIGH
Day Range48.50
49.77
52 Week Range32.78
53.00
Ratios
P/B Ratio58.55
Revenue$829.25M
Operating M. %48.78%
Earnings$281.59M
Earnings Growth %39.31%
EBITDA Margin %55.28%
ROE %261.68%
EPS2.41

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

info
There's no data available for Analyst Forecast

Analyst Ratings

info
There's no data available for Analyst Ratings

Correlated Companies

PRICE$878.45
24H (%)arrow_drop_down0.55%
24H ($)-$4.88
MARKET CAP$771.28B
PRICE$497.12
24H (%)arrow_drop_down0.03%
24H ($)-$0.17
MARKET CAP$443.63B
PRICE$145.53
24H (%)arrow_drop_up0.06%
24H ($)$0.09
MARKET CAP$347.62B
PRICE$129.48
24H (%)arrow_drop_up0.08%
24H ($)$0.11
MARKET CAP$318.88B

About Halozyme Therapeutics (HALO)

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; NOCDURNA, a sublingual tablet to treat nocturia due to nocturnal polyuria; TLANDO, an oral formulation for testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of multiple blood cancer; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergy and immunology; Sumatriptan injection for migraines; exenatide and teriparatide injections; Makena, a progestin drug to reduce the risk of preterm birth; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.
Headquarters
San Diego
Employees
393
Exchange
NASDAQ
add Halozyme Therapeutics  to watchlist

Keep an eye on Halozyme Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Halozyme Therapeutics 's (HALO) price per share?

The current price per share for Halozyme Therapeutics (HALO) is $49.5. The stock has seen a price change of -$0.12 recently, indicating a -0.24% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Halozyme Therapeutics (HALO)?

For Halozyme Therapeutics (HALO), the 52-week high is $53, which is 7.07% from the current price. The 52-week low is $32.78, the current price is 51.01% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Halozyme Therapeutics (HALO) a growth stock?

Halozyme Therapeutics (HALO) has shown an average price growth of 0.41% over the past three years. It has received a score of 43 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Halozyme Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Halozyme Therapeutics (HALO) stock price performance year to date (YTD)?

As of the latest data, Halozyme Therapeutics (HALO) has a year-to-date price change of 32.39%. Over the past month, the stock has experienced a price change of 8.03%. Over the last three months, the change has been 21.15%. Over the past six months, the figure is 26.86%. Looking at a longer horizon, the five-year price change stands at 206.31%.

help
Is Halozyme Therapeutics (HALO) a profitable company?

Halozyme Therapeutics (HALO) has a net income of $281.59M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 76.8% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 48.78% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $829.25M, with a revenue growth rate of 25.62%, providing insight into the company's sales performance and growth. The gross profit is $636.89M. Operating income is noted at $337.57M. Furthermore, the EBITDA is $463.92M.

help
What is the market capitalization of Halozyme Therapeutics (HALO)?

Halozyme Therapeutics (HALO) has a market capitalization of $5.44B. The average daily trading volume is 1.71M, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level